Gingernone A is a Better-than-D+Q Senolytic
A post in Lifespan.io discusses a recent paper published last month in PLoS One in which the polyphenol Gingernone A, a strong component of Ginger Root Extract, when applied in sufficient concentration to senescent human fibroblasts (skin cells), acts as a somewhat better senolytic than D+Q. This is very interesting because Ginger Root Extract is cheap. Swanson sells 60 x 200 mg capsules for $5.84, whereas Bristol-Meyers-Squibb charges around $1,000 for one senolytic-size dose of Dasatinib.
Like Fisetin and Quercetin, Gingernone A is not very water-soluble, about 3.6 mg/liter, so It's probably necessary to take a lot to get some into the bloodstream, and taking Bioperine at the same time should help.
I just ordered some Ginger Root Extract from Swanson and plan to use about 2 g/day of it (10 caps) along with Fisetin and D+Q in our next senolytic burst-dose session in a couple of months.
-
I should add that in Figure 1 of the paper describing the identification of Gingerenone A (note spelling, which was incorrect above) as a senolytic, the authors tried two concentration levels, 1 part in 500 and 1 part in 200. They found that the weaker 1:500 concentration showed no senolytic effect, while the 1:200 concentration show a senolytic effect stronger than that of D+Q. There is apparently a threshold before there is any senescent cell clearance. The moral is that in burst dosing one should aim high and that small daily doses at small concentrations are unlikely to do much.